Nisha Dabhi1, Stylianos Pikis1, Georgios Mantziaris1, Manjul Tripathi2, Ronald Warnick3, Selcuk Peker4, Yavuz Samanci4, Assaf Berger5, Kenneth Bernstein6, Douglas Kondziolka5, Ajay Niranjan7, L Dade Lunsford7, Jason P Sheehan8. 1. Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, 22908, USA. 2. Department of Neurosurgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 3. Gamma Knife Center, The Jewish Hospital, Cincinnati, OH, USA. 4. Department of Neurosurgery, Koc University School of Medicine, Istanbul, Turkey. 5. Department of Neurosurgery, New York University Langone, New York, NY, USA. 6. Department of Radiation Oncology, New York University Langone, New York, NY, USA. 7. Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 8. Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, 22908, USA. jps2f@virginia.edu.
Abstract
BACKGROUND: Surgical removal has been performed as the first line treatment for symptomatic or enlarging hypoglossal schwannomas (HS). Stereotactic radiosurgery (SRS) offers a minimally invasive approach that may afford long-term tumor control for patients with HS particularly those who refuse or are unfit for surgery. This study evaluates outcomes after SRS performed for both newly diagnosed and residual tumors after incomplete resection. METHODS: This retrospective, multi-institutional study involved patients treated with adjuvant or primary SRS for HS. The study end-points included local tumor response, clinical outcomes, and procedure-related complications. All the patients had Gamma Knife SRS. RESULTS: The cohort included 12 patients (five females), median age at SRS 49.5 years (range, 37-76)]. The median tumor target volume was 5.9 cm3 (range, 0.7-27.23). At median imaging follow-up of 37 months (range, 6-153), tumor control was achieved in 11 patients. Tumor enlargement that was managed with surgical resection was noted at the 6-month follow-up in one patient. At median clinical follow-up of 30.5 months (range, 6-157), stability, or improvement of all pre-SRS signs and symptoms was noted in nine patients. Two patients experienced worsening of at least one pre-existing symptoms or sign. New-onset trapezius weakness was noted in one patient and tongue atrophy in two patients. CONCLUSION: Single-fraction SRS appears to be a safe and effective upfront and adjuvant treatment option for HS. SRS may be recommended as an alternative to surgery for patients presenting with HS or as an adjuvant treatment following subtotal resection and at HS recurrence.
BACKGROUND: Surgical removal has been performed as the first line treatment for symptomatic or enlarging hypoglossal schwannomas (HS). Stereotactic radiosurgery (SRS) offers a minimally invasive approach that may afford long-term tumor control for patients with HS particularly those who refuse or are unfit for surgery. This study evaluates outcomes after SRS performed for both newly diagnosed and residual tumors after incomplete resection. METHODS: This retrospective, multi-institutional study involved patients treated with adjuvant or primary SRS for HS. The study end-points included local tumor response, clinical outcomes, and procedure-related complications. All the patients had Gamma Knife SRS. RESULTS: The cohort included 12 patients (five females), median age at SRS 49.5 years (range, 37-76)]. The median tumor target volume was 5.9 cm3 (range, 0.7-27.23). At median imaging follow-up of 37 months (range, 6-153), tumor control was achieved in 11 patients. Tumor enlargement that was managed with surgical resection was noted at the 6-month follow-up in one patient. At median clinical follow-up of 30.5 months (range, 6-157), stability, or improvement of all pre-SRS signs and symptoms was noted in nine patients. Two patients experienced worsening of at least one pre-existing symptoms or sign. New-onset trapezius weakness was noted in one patient and tongue atrophy in two patients. CONCLUSION: Single-fraction SRS appears to be a safe and effective upfront and adjuvant treatment option for HS. SRS may be recommended as an alternative to surgery for patients presenting with HS or as an adjuvant treatment following subtotal resection and at HS recurrence.
Authors: Isabelle M Germano; Jason Sheehan; Johnathan Parish; Tyler Atkins; Anthony Asher; Constantinos G Hadjipanayis; Stuart H Burri; Sheryl Green; Jeffrey J Olson Journal: Neurosurgery Date: 2018-02-01 Impact factor: 4.654
Authors: Daniel D Cavalcanti; Nikolay L Martirosyan; Ketan Verma; Sam Safavi-Abbasi; Randall W Porter; Nicholas Theodore; Volker K H Sonntag; Curtis A Dickman; Robert F Spetzler Journal: J Neurosurg Date: 2010-07-09 Impact factor: 5.115
Authors: Shivani Bindal; Tarek Y El Ahmadieh; Aaron Plitt; Salah G Aoun; Om James Neeley; Najib E El Tecle; Samuel Barnett; Wayne Gluf Journal: J Clin Neurosci Date: 2018-11-22 Impact factor: 1.961
Authors: Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Eva Dombi; Simone L Ardern-Holmes; Dusica Babovic-Vuksanovic; Fred G Barker; Steve Connor; D Gareth Evans; Michael J Fisher; Stephane Goutagny; Gordon J Harris; Diego Jaramillo; Matthias A Karajannis; Bruce R Korf; Victor Mautner; Scott R Plotkin; Tina Y Poussaint; Kent Robertson; Chie-Schin Shih; Brigitte C Widemann Journal: Neurology Date: 2013-11-19 Impact factor: 9.910
Authors: Anne Balossier; Jean Régis; Nicolas Reyns; Pierre-Hugues Roche; Roy Thomas Daniel; Mercy George; Mohamed Faouzi; Marc Levivier; Constantin Tuleasca Journal: Neurosurg Rev Date: 2021-04-13 Impact factor: 3.042